Table 1.
Univariate and multivariate Cox regression analysis for DFS and OS of 32 patients with ENKL
| Variables | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| HR (95 % CI) | P value | HR (95 % CI) | P value | |
| In MDSC population | ||||
| Disease-free survival | ||||
| Age (<40/≥40) | 1.259 (0.355–4.470) | 0.722 | ||
| Gender (female/male) | 1.930 (0.544–6.852) | 0.309 | ||
| Ann Arbor stage (I/II–IV) | 3.434 (0.959–12.293) | 0.045* | 1.748 (0.368–8.295) | 0.482 |
| Subtypes (UNKTL/EUNKTL) | 1.306 (0.277–6.164) | 0.736 | ||
| B symptoms (no/yes) | 55.563 (0.323–9550.869) | 0.126 | ||
| LDH level (normal/elevated) | 3.834 (1.091–13.474) | 0.036* | 0.875 (0.070–10.912) | 0.918 |
| KPI score (0–1/2–4) | 3.417 (0.881–13.250) | 0.076 | ||
| PIT score (0–1/2–4) | 3.031 (0.852–10.785) | 0.084 | ||
| IPI score (0–1/2–5) | 3.718 (1.074–12.874) | 0.038* | 5.327 (0.324–87.663) | 0.242 |
| MDSC frequency (low/high)a | 10.216 (1.285–81.244) | 0.028* | 21.633 (1.892–247.378) | 0.013* |
| Overall survival | ||||
| Age (<40/≥40) | 1.370 (0.342–5.491) | 0.656 | ||
| Gender (female/male) | 1.798 (0.449–7.198) | 0.407 | ||
| Ann Arbor stage (I/II–IV) | 3.894 (0.969–15.650) | 0.046* | 2.090 (0.374–11.678) | 0.401 |
| Subtypes (UNKTL/EUNKTL) | 1.515 (0.315–7.320) | 0.603 | ||
| B symptoms (no/yes) | 53.653 (0.233–12,381.115) | 0.151 | ||
| LDH level (normal/elevated) | 5.011 (1.318–19.059) | 0.018* | 1.155 (0.085–15.622) | 0.914 |
| KPI score (0–1/2–4) | 2.723 (0.680–10.908) | 0.157 | ||
| PIT score (0–1/2–4) | 4.063 (1.014–16.290) | 0.048* | 1.284 (0.095–17.339) | 0.851 |
| IPI score (0–1/2–5) | 4.814 (1.289–17.977) | 0.019* | 6.153 (0.361–104.775) | 0.209 |
| MDSC frequency (low/high) | 8.644 (1.073–69.636) | 0.043* | 19.593 (1.694–226.646) | 0.017* |
| In Mo-MDSC population | ||||
| Disease-free survival | ||||
| Age (<40/≥40) | 1.259 (0.355–4.470) | 0.722 | ||
| Gender (female/male) | 1.930 (0.544–6.852) | 0.309 | ||
| Ann Arbor stage (I/II–IV) | 3.434 (0.959–12.293) | 0.045* | 1.549 (0.402–5.970) | 0.525 |
| Subtypes (UNKTL/EUNKTL) | 1.306 (0.277–6.164) | 0.736 | ||
| B symptoms (no/yes) | 55.563 (0.323–9550.869) | 0.126 | ||
| LDH level (normal/elevated) | 3.834 (1.091–13.474) | 0.036* | 1.843 (0.211–16.130) | 0.581 |
| KPI score (0–1/2–4) | 3.417 (0.881–13.250) | 0.076 | ||
| PIT score (0–1/2–4) | 3.031 (0.852–10.785) | 0.084 | ||
| IPI score (0–1/2–5) | 3.718 (1.074–12.874) | 0.038* | 3.181 (0.358–28.269) | 0.299 |
| Mo-MDSC frequency (low/high)a | 5.956 (1.249–28.411) | 0.025* | 7.873 (1.467–42.238) | 0.016* |
| Overall survival | ||||
| Age (<40/≥40) | 1.370 (0.342–5.491) | 0.656 | ||
| Gender (female/male) | 1.798 (0.449–7.198) | 0.407 | ||
| Ann Arbor stage (I/II–IV) | 3.894 (0.969–15.650) | 0.046* | 2.275 (0.436–11.878) | 0.330 |
| Subtypes (UNKTL/EUNKTL) | 1.515 (0.315–7.320) | 0.603 | ||
| B symptoms (no/yes) | 53.653 (0.233–12,381.115) | 0.151 | ||
| LDH level (normal/elevated) | 5.011 (1.318–19.059) | 0.018* | 2.684 (0.240–30.257) | 0.423 |
| KPI score (0–1/2–4) | 2.723 (0.680–10.908) | 0.157 | ||
| PIT score (0–1/2–4) | 4.063 (1.014–16.290) | 0.048* | 0.544 (0.039–7.604) | 0.651 |
| IPI score (0–1/2–5) | 4.814 (1.289–17.977) | 0.019* | 4.432 (0.342–57.364) | 0.254 |
| Mo-MDSC frequency (low/high) | 4.890 (1.004–23.809) | 0.049* | 6.867 (1.243–37.948) | 0.027* |
DFS disease-free survival, OS overall survival, HR hazard ratio, CI confidence interval, LDH lactate dehydrogenase, IPI International Prognostic Index, KPI Korean Prognostic Index, PIT Peripheral T cell lymphoma Prognostic Index
* Significant difference
aMDSC (high/low) is based on the median value of the MDSC density